Stockscreener 앱 받기
0.1174
3.93%
-0.0048
시간 외 거래:
.11
-0.0074
-6.30%
전일 마감가:
$0.1222
열려 있는:
$0.1229
하루 거래량:
2.85M
Relative Volume:
0.88
시가총액:
$1.30M
수익:
-
순이익/손실:
$-11.38M
주가수익비율:
-0.00423
EPS:
-27.73
순현금흐름:
$-12.72M
1주 성능:
-10.11%
1개월 성능:
-61.15%
6개월 성능:
-98.93%
1년 성능:
-67.34%
1일 변동 폭
$0.1161
$0.123
1주일 범위
$0.1046
$0.144
52주 변동 폭
$0.1046
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
명칭
Windtree Therapeutics Inc
전화
(215) 488-9300
주소
2600 KELLY ROAD, WARRINGTON, PA
WINT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.1174 | 1.30M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-26 | 개시 | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc 주식(WINT)의 최신 뉴스
Windtree Therapeutics Inc (NASDAQ: WINT) Stock Dropped -60.95% Over A Month – Any Room To Run? - Marketing Sentinel
Windtree Therapeutics enacts reverse stock split, expands equity plan - MSN
WINT: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
WINT (Windtree Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
It makes sense and dollars to buy Windtree Therapeutics Inc (WINT) stock - SETE News
Windtree Therapeutics enacts reverse stock split, expands equity plan By Investing.com - Investing.com Australia
This morning’s top pick is Windtree Therapeutics Inc (NASDAQ:WINT) - US Post News
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 72.4% - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms - MSN
What Did We Find About Insider Trading At Windtree Therapeutics Inc (NASDAQ: WINT)? - Stocks Register
Windtree Therapeutics Announces Offer to Reduce Conversion Price of Series C Preferred Stock - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms By Investing.com - Investing.com Australia
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MSN
Windtree Therapeutics Reports Q3 Results and Highlights Key Business Achievements - MSN
Windtree Therapeutics Secures Patent in Japan for Cancer Treatment Platform - MSN
Windtree Therapeutics Highlights Istaroxime’s Promise for Cardiogenic Shock - MSN
Windtree Therapeutics Appoints Leanne Kelly to Board of Directors and Audit Committee - Defense World
Windtree Therapeutics Appoints Leanne Kelly to Board, Advances New Growth Strategy - MSN
Warrington’s Windtree Therapeutics Eyes Acquisitions to Stay Afloat - MSN
Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - The Manila Times
Windtree Therapeutics Secures Key Japanese Patent for Novel Cancer Treatment Platform - StockTitan
Windtree Strengthens Global Intellectual Property Portfolio - GlobeNewswire
Windtree Therapeutics appoints new board member By Investing.com - Investing.com Australia
Windtree Therapeutics, Inc. Appoints Leanne Kelly to Its Board of Directors and Chair of the Audit Committee - Marketscreener.com
Windtree Therapeutics Strengthens Leadership Amid Strategic Shift - TipRanks
Windtree Therapeutics appoints new board member - Investing.com
Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - Yahoo Finance
Windtree Therapeutics Inc (WINT): Worth A Small Bite At $0.27 - Stocks Register
Windtree Therapeutics Unveils New Strategy to Drive Revenue Growth - MSN
Windtree Therapeutics Announces New Corporate Strategy in Recent Press Release - Defense World
Windtree Therapeutics adopts new acquisition strategy By Investing.com - Investing.com Nigeria
Windtree Therapeutics seeks acquisitions to stop slide as stock hits new low - The Business Journals
Windtree Therapeutics adopts new acquisition strategy - Investing.com India
Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline - The Manila Times
Windtree Therapeutics Unveils Bold Revenue Strategy: Plans FDA-Approved Product Acquisitions - StockTitan
Windtree Therapeutics Advances Heart Failure Treatment in New Clinical Trials - MSN
WINT stock touches 52-week low at $0.29 amid steep annual decline - Investing.com
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Increase in Short Interest - Defense World
WINT stock touches 52-week low at $0.32 amid steep annual decline - Investing.com
Windtree Announces Istaroxime Presentation By Cardiogenic - GlobeNewswire
Windtree's Istaroxime Shows Breakthrough Results in Phase 2 Heart Failure Trials, Advances to Phase 3 - StockTitan
Windtree Therapeutics Inc (WINT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.03%
자본화:
|
볼륨(24시간):